A drug-delivery pharmaceutical company, SUDA Pharmaceuticals has recently identified the use of platelets as surrogate biomarkers in cancer risk that can potentially reduce the economic burden from cancer incidence at risk individuals.
SUDA Pharmaceuticals Ltd (ASX: SUD) headquartered in Perth, Western Australia focuses on oro-mucosal drug delivery technology in the development of low-risk pharmaceuticals using a novel application of existing drugs which are out of patent restriction. The company re-formulates these drugs to provide patentable products that are capable of improving the health and lifestyle of patients.
In the recent development update, SUDA announced that its anti-thrombotic agent, anagrelide, has shown the promising result as a novel anti-cancer agent. Its anagrelide patent provides the potential prophylactic use of anagrelide as a chemo-preventative product. That means it has the potential to identify risk patients and then provide them prophylactic platelet lowering therapy with an anagrelide oral spray.
The company believes that anagrelide offers a novel and valuable first-in-class treatment option for cancer as it could be complementary to many cancer treatments by reducing platelet numbers which would minimise the proliferative and protective effect that platelets exhibit on metastatic cells.
SUDA focuses on administering drugs through the oral mucosa, which is the moist lining of the oral cavity, i.e., tongue, cheeks, gums and palate. The oral spray application is supported for the several benefits that it has including ease of use, reduced side effect, lower dosage and faster response time. SUDA has therefore developed its proprietary OroMist® oro-mucosal drug delivery technology which is utilised in the formulation and development of its oral-spray products aimed at the treatment of insomnia, nausea and malaria among its wide range of product category.
Now, SUDA is progressing in the development of cancer-prevention technology. The studies have demonstrated that the cancer burden and deaths from cancer are increasing worldwide with more than 14 million cases of cancer reported every year and it is expected that the number will reach 22 million globally by 2030 (Bray et al., 2015).
On commercialisation front, the company aims to add value through to a stage where it can secure licensing or collaborative development agreements to the supply of its proprietary products across the globe. SUDA also seeks collaborations where it can re-formulate the existing drugs of its partner company into a patentable product or line extensions for existing franchises.
The company has recently partnered with Chinese Pharmaceuticals company for the development and commercialisation of its ZolpiMist™ oral spray that is aimed at the treatment of insomnia in China. However, it is pending for approval from the Chinese Food and Drug Administration (CFDA), once approved, the product would be the first imported fast-acting oral spray of zolpidem available in China.
Moreover, the company holds IP covering over 300 extensively used active pharmaceuticals ingredients formulated into oral spays. Its product pipeline covers oral sprays for sumatriptan for migraine, sildenafil for erectile dysfunction, ondansetron for chemotherapy-induced nausea, and midazolam for pre-procedural anxiety and epileptic seizures.
SUD last traded at $0.005 with a market capitalisation of $12.91 million as at 20 March 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.